We aimed to assess the influence of metabolic syndrome in fibrosis regression (by liver-stiffness measurement and serological scores) and its relationship with the expression of lysyl oxidase-like-2 as a potential goal of antifibrotic therapy. The gene discussed is LOXL2; the disease is fibrosis.